Document Detail


Leucocyte interferon-alpha retreatment for chronic hepatitis C patients previously intolerant to other interferons.
MedLine Citation:
PMID:  9795917     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The activity and tolerability of a retreatment cycle with leucocyte interferon-alpha (IFN-alpha) (6 million units (MU) three times weekly for 12 months) was evaluated in a group of 22 hepatitis C patients who had been intolerant to a previous course of lymphoblastoid IFN-alpha. Seven patients (31%) discontinued the new therapy owing to either a lack of response (six patients) or to severe leucopenia (one patient). Fifteen patients (68%) completed the 12-month treatment: all had a biochemical response and 10 (45%) also had disappearance of serum HCV RNA (complete response). Mild adverse reactions (fever, headaches and diarrhoea) were seen in these patients during retreatment. After 12 months of follow-up, 11 patients (50%) still maintained the biochemical response (long-term response); seven of these patients (32%) were also negative for serum HCV RNA. Biochemical and complete responses, at the end of both treatment and follow-up, were similar to those seen with lymphoblastoid IFN-alpha. The full dose of leucocyte IFN-alpha, when used in patients previously intolerant to the same dosage of lymphoblastoid IFN-alpha, was better tolerated: only one of the 15 patients who completed the 12-month treatment had a severe adverse event leading to withdrawal vs 22 of 68 patients treated with lymphoblastoid IFN-alpha. Furthermore, there were no manifestations of serological or clinical autoimmunity caused by leucocyte IFN-alpha, even in patients with autoantibodies associated with previous IFN therapy.
Authors:
B Cacopardo; F Benanti; G Brancati; F Romano; A Nunnari
Related Documents :
12599227 - Elevation of cytokine levels in cachectic patients with prostate carcinoma.
10888707 - The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tum...
9869787 - Interferon-induced protein 10 and interleukin 8. c-x-c chemokines present in proliferat...
11549517 - Parameters influencing membrane cd14 expression and soluble cd14 levels in sepsis.
12915967 - Earlier appearance and higher incidence of the rectoanal relaxation reflex in patients ...
8984087 - Intravenous magnesium sulfate rapidly alleviates headaches of various types.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of viral hepatitis     Volume:  5     ISSN:  1352-0504     ISO Abbreviation:  J. Viral Hepat.     Publication Date:  1998 Sep 
Date Detail:
Created Date:  1999-01-04     Completed Date:  1999-01-04     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9435672     Medline TA:  J Viral Hepat     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  333-9     Citation Subset:  IM    
Affiliation:
Infectious Diseases Institute, University of Catania, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antiviral Agents / adverse effects,  therapeutic use*
Female
Follow-Up Studies
Hepatitis C, Chronic / drug therapy*
Humans
Interferon-alpha / adverse effects,  therapeutic use*
Interferons / therapeutic use
Male
Middle Aged
Time Factors
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Interferon-alpha; 9008-11-1/Interferons

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Long-term retreatment in chronic hepatitis C patients who were non-responders to an initial course o...
Next Document:  Significance of antibodies to the recombinant E2 protein of hepatitis G virus in haemodialysis patie...